Bottom line
A two-component research-peptide combination pairing BPC-157 (cytoprotective/angiogenic pentadecapeptide) with KPV (Lys-Pro-Val, anti-inflammatory tripeptide derived from alpha-MSH). Often marketed as a GI-focused alternative to broader blends, and as a component of KLOW70 (which adds GHK-Cu without TB-500). No published combination study exists.
No established or recommended human dose.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| KLOW70 variant (2026) | BPC-157, KPV, GHK-Cu | 10 / 10 / 50 mg | Vendor-declared |
| Available as standalone combination | BPC-157, KPV | Typically 10 / 10 mg | Vendor-dependent |
This combination exists as a distinct pairing (especially in GI research contexts) or as KLOW70 (which adds GHK-Cu but omits TB-500). Composition varies.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| BPC-157 | Preclinical VEGFR2/NO angiogenesis; GI mucosal protection; oral stability; tendon repair; nitric oxide pathway | No published study of BPC-157 + KPV combination | KPV is PepT1 substrate (oral uptake); BPC-157 is orally stable; no co-formulation stability data |
| KPV | Tripeptide Lys-Pro-Val; α-MSH C-terminal fragment; NF-κB inhibition (Dalmasso 2008); anti-inflammatory in colitis models (DSS, TNBS); PepT1-mediated intestinal uptake; ~50% reduction in myeloperoxidase in DSS model | No published combination study with BPC-157 | — |
The mechanistic rationale for BPC-157 + KPV as a GI-focused combination: BPC-157 provides cytoprotection and angiogenesis, KPV adds NF-κB-mediated anti-inflammatory activity via PepT1 uptake in intestinal epithelial cells.
Combination-specific studies
No published study tests the BPC-157 + KPV combination. The rationale rests entirely on separate component evidence.
Safety and interaction uncertainties
KPV's NF-κB inhibition may theoretically delay resolution-phase inflammation
BPC-157's NO modulation may interact with anti-inflammatory pathways
No combination-specific safety data
Fixed-ratio blends prevent independent dose adjustment
Regulatory and product-quality notes
Neither component is FDA-approved
Both sold as "research use only"
KPV occasionally appears in cosmetic products
WADA: BPC-157 is listed under S0. KPV is not explicitly named in the 2026 List; an athlete should obtain a case-specific determination rather than infer status from the blend or from KPV's peptide class.
Evidence gaps
No combination study of any kind
No co-stability data
No pharmacokinetic interaction data
No dose-ratio optimisation
No human data for either component for GI repair claims
Sources
AminoCore Research. KLOW Blend Analysis (for KLOW70 variant). https://aminocoreresearch.com/articles/klow-blend-bpc-157-tb-500-ghk-cu-kpv accessed 2026-08-06.
Dalmasso G, et al. Am J Physiol Gastrointest Liver Physiol. 2008;295(1):G43-G54. PMID 18436621.
Durham Peptides. Inside the KLOW Blend (section on KPV and BPC-157). https://www.durhampeptides.ca/post/inside-klow-blend-four-component-breakdown accessed 2026-08-06.
BergdorfBio. KLOW Stack Guide (component details). https://bergdorfbio.com/en/us/guides/klow-stack-leitfaden accessed 2026-08-06.
World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf